Subscribe to our newsletter

News

August 16, 2017
VentureMed Group Raises $15 Million Series B Equity Financing

VentureMed Group®, Inc., ("VMG" or the "Company") a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 million in new equity financing...

May 30, 2017
Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies...

May 12, 2017
Patrick Amstutz Appointed as Chief Executive Officer

Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies...

April 6, 2017
Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies

Long-term venture capital investors holding reduced to 28% of share capital...

March 30, 2017
Symetis and Boston Scientific reach USD 435 million purchase agreement

Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment...